vs
Side-by-side financial comparison of Celanese Corp (CE) and SELECT MEDICAL HOLDINGS CORP (SEM). Click either name above to swap in a different company.
Celanese Corp is the larger business by last-quarter revenue ($2.2B vs $1.4B, roughly 1.6× SELECT MEDICAL HOLDINGS CORP). SELECT MEDICAL HOLDINGS CORP runs the higher net margin — 1.4% vs 0.6%, a 0.8% gap on every dollar of revenue. On growth, SELECT MEDICAL HOLDINGS CORP posted the faster year-over-year revenue change (6.4% vs -7.0%). Celanese Corp produced more free cash flow last quarter ($168.0M vs $5.2M). Over the past eight quarters, SELECT MEDICAL HOLDINGS CORP's revenue compounded faster (2.8% CAGR vs -8.1%).
Celanese Corporation, formerly known as Hoechst Celanese, is an American technology and specialty materials company headquartered in Irving, Texas. It is a Fortune 500 corporation. The company is the world's leading producer of acetic acid, producing about 1.95 million tonnes per year, representing approximately 20% of global production. Celanese is also the world's largest producer of vinyl acetate monomer (VAM).
Select Medical is a healthcare company based in Pennsylvania. It owns long-term acute care and inpatient rehabilitation hospitals, as well as occupational health and physical therapy clinics. Select Medical is a subsidiary of Select Medical Holdings, which is listed on the New York Stock Exchange.
CE vs SEM — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $2.2B | $1.4B |
| Net Profit | $14.0M | $20.2M |
| Gross Margin | 19.1% | — |
| Operating Margin | 4.0% | 4.6% |
| Net Margin | 0.6% | 1.4% |
| Revenue YoY | -7.0% | 6.4% |
| Net Profit YoY | 100.7% | 225.7% |
| EPS (diluted) | $0.13 | $0.17 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $2.2B | $1.4B | ||
| Q3 25 | $2.4B | $1.4B | ||
| Q2 25 | $2.5B | $1.3B | ||
| Q1 25 | $2.4B | $1.4B | ||
| Q4 24 | $2.4B | $1.3B | ||
| Q3 24 | $2.6B | $1.3B | ||
| Q2 24 | $2.7B | $1.3B | ||
| Q1 24 | $2.6B | $1.3B |
| Q4 25 | $14.0M | $20.2M | ||
| Q3 25 | $-1.4B | $28.8M | ||
| Q2 25 | $199.0M | $40.6M | ||
| Q1 25 | $-21.0M | $56.7M | ||
| Q4 24 | $-1.9B | $-16.1M | ||
| Q3 24 | $116.0M | $55.6M | ||
| Q2 24 | $155.0M | $77.6M | ||
| Q1 24 | $121.0M | $96.9M |
| Q4 25 | 19.1% | — | ||
| Q3 25 | 21.5% | — | ||
| Q2 25 | 21.1% | — | ||
| Q1 25 | 19.9% | — | ||
| Q4 24 | 22.7% | — | ||
| Q3 24 | 23.5% | — | ||
| Q2 24 | 24.2% | — | ||
| Q1 24 | 21.2% | — |
| Q4 25 | 4.0% | 4.6% | ||
| Q3 25 | -52.7% | 5.4% | ||
| Q2 25 | 9.2% | 6.5% | ||
| Q1 25 | 7.0% | 8.3% | ||
| Q4 24 | -59.3% | 1.6% | ||
| Q3 24 | 9.4% | 4.3% | ||
| Q2 24 | 9.4% | 5.8% | ||
| Q1 24 | 8.0% | 9.0% |
| Q4 25 | 0.6% | 1.4% | ||
| Q3 25 | -56.1% | 2.1% | ||
| Q2 25 | 7.9% | 3.0% | ||
| Q1 25 | -0.9% | 4.2% | ||
| Q4 24 | -80.8% | -1.2% | ||
| Q3 24 | 4.4% | 4.4% | ||
| Q2 24 | 5.8% | 6.1% | ||
| Q1 24 | 4.6% | 7.3% |
| Q4 25 | $0.13 | $0.17 | ||
| Q3 25 | $-12.39 | $0.23 | ||
| Q2 25 | $1.81 | $0.32 | ||
| Q1 25 | $-0.19 | $0.44 | ||
| Q4 24 | $-17.50 | $-0.12 | ||
| Q3 24 | $1.06 | $0.43 | ||
| Q2 24 | $1.41 | $0.60 | ||
| Q1 24 | $1.10 | $0.75 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $26.5M |
| Total DebtLower is stronger | $11.4B | $1.8B |
| Stockholders' EquityBook value | $4.0B | $1.7B |
| Total Assets | $21.7B | $5.9B |
| Debt / EquityLower = less leverage | 2.81× | 1.06× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $26.5M | ||
| Q3 25 | — | $60.1M | ||
| Q2 25 | — | $52.3M | ||
| Q1 25 | — | $53.2M | ||
| Q4 24 | — | $59.7M | ||
| Q3 24 | — | $191.5M | ||
| Q2 24 | — | $111.2M | ||
| Q1 24 | — | $92.6M |
| Q4 25 | $11.4B | $1.8B | ||
| Q3 25 | $11.7B | $1.7B | ||
| Q2 25 | $12.7B | $1.8B | ||
| Q1 25 | $12.4B | $1.8B | ||
| Q4 24 | $11.1B | $1.7B | ||
| Q3 24 | $11.3B | $3.1B | ||
| Q2 24 | $11.1B | $3.6B | ||
| Q1 24 | $11.0B | $3.8B |
| Q4 25 | $4.0B | $1.7B | ||
| Q3 25 | $4.0B | $1.7B | ||
| Q2 25 | $5.3B | $1.7B | ||
| Q1 25 | $5.2B | $1.7B | ||
| Q4 24 | $5.2B | $1.7B | ||
| Q3 24 | $7.3B | $1.9B | ||
| Q2 24 | $7.2B | $1.4B | ||
| Q1 24 | $7.1B | $1.4B |
| Q4 25 | $21.7B | $5.9B | ||
| Q3 25 | $22.2B | $5.7B | ||
| Q2 25 | $23.7B | $5.7B | ||
| Q1 25 | $23.2B | $5.7B | ||
| Q4 24 | $22.9B | $5.6B | ||
| Q3 24 | $25.9B | $8.0B | ||
| Q2 24 | $25.8B | $7.9B | ||
| Q1 24 | $26.0B | $7.9B |
| Q4 25 | 2.81× | 1.06× | ||
| Q3 25 | 2.95× | 1.03× | ||
| Q2 25 | 2.41× | 1.10× | ||
| Q1 25 | 2.39× | 1.03× | ||
| Q4 24 | 2.14× | 1.01× | ||
| Q3 24 | 1.56× | 1.62× | ||
| Q2 24 | 1.54× | 2.54× | ||
| Q1 24 | 1.56× | 2.75× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $252.0M | $64.3M |
| Free Cash FlowOCF − Capex | $168.0M | $5.2M |
| FCF MarginFCF / Revenue | 7.6% | 0.4% |
| Capex IntensityCapex / Revenue | 3.8% | 4.2% |
| Cash ConversionOCF / Net Profit | 18.00× | 3.19× |
| TTM Free Cash FlowTrailing 4 quarters | $803.0M | $117.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $252.0M | $64.3M | ||
| Q3 25 | $447.0M | $175.3M | ||
| Q2 25 | $410.0M | $110.3M | ||
| Q1 25 | $37.0M | $-3.5M | ||
| Q4 24 | $494.0M | $125.4M | ||
| Q3 24 | $79.0M | $181.0M | ||
| Q2 24 | $292.0M | $278.2M | ||
| Q1 24 | $101.0M | $-66.7M |
| Q4 25 | $168.0M | $5.2M | ||
| Q3 25 | $383.0M | $122.2M | ||
| Q2 25 | $317.0M | $45.6M | ||
| Q1 25 | $-65.0M | $-55.8M | ||
| Q4 24 | $389.0M | $62.0M | ||
| Q3 24 | $-9.0M | $130.3M | ||
| Q2 24 | $187.0M | $222.6M | ||
| Q1 24 | $-36.0M | $-119.2M |
| Q4 25 | 7.6% | 0.4% | ||
| Q3 25 | 15.8% | 9.0% | ||
| Q2 25 | 12.5% | 3.4% | ||
| Q1 25 | -2.7% | -4.1% | ||
| Q4 24 | 16.4% | 4.7% | ||
| Q3 24 | -0.3% | 10.2% | ||
| Q2 24 | 7.1% | 17.4% | ||
| Q1 24 | -1.4% | -9.0% |
| Q4 25 | 3.8% | 4.2% | ||
| Q3 25 | 2.6% | 3.9% | ||
| Q2 25 | 3.7% | 4.8% | ||
| Q1 25 | 4.3% | 3.9% | ||
| Q4 24 | 4.4% | 4.8% | ||
| Q3 24 | 3.3% | 4.0% | ||
| Q2 24 | 4.0% | 4.3% | ||
| Q1 24 | 5.2% | 4.0% |
| Q4 25 | 18.00× | 3.19× | ||
| Q3 25 | — | 6.09× | ||
| Q2 25 | 2.06× | 2.72× | ||
| Q1 25 | — | -0.06× | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.68× | 3.25× | ||
| Q2 24 | 1.88× | 3.59× | ||
| Q1 24 | 0.83× | -0.69× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CE
| Engineered Materials | $1.3B | 58% |
| Acetyl Chain | $940.0M | 43% |
SEM
| Critical Illness Recovery Hospitals | $629.7M | 45% |
| Health Care Patient Service Non Medicare | $428.6M | 31% |
| Rehabilitation Hospitals | $339.2M | 24% |
